Physician profile
Hannah E Clark
NPI 1245614726
$4,491.35
in general payments reported to CMS, 2019-2025
15 companies · $2,784 in 2025
The $2,784 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $101 · 2022: $352 · 2023: $534 · 2024: $720 · 2025: $2,784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,250 · Food and Beverage: $1,603 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,250.00 |
| Food and Beverage | $1,603.23 |
| Education | $184.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma Global Development | $2,250.00 | 2025 | Veozah |
| Astellas Pharma US INC | $840.80 | 2021-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $478.97 | 2024-2025 | Reblozyl, Opdivo |
| Regeneron Healthcare Solutions, INC. | $244.69 | 2024-2025 | Libtayo, Eylea Hd |
| Kite Pharma, INC. | $244.12 | 2022-2023 | Yescarta |
| Alexion Pharmaceuticals, INC. | $134.98 | 2025 | Ultomiris |
| Abbvie INC. | $107.51 | 2021-2023 | |
| Pfizer INC. | $37.74 | 2023-2024 | |
| Daiichi Sankyo INC. | $31.61 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.71 | 2022-2023 | |
| Exeltis, USA INC. | $23.07 | 2024 | Slynd |
| Stemline Therapeutics INC. | $20.81 | 2023 | Orserdu |
| Coopersurgical, INC. | $19.01 | 2024 | Paragard T 380a |
| Ascend Therapeutics US, LLC | $15.56 | 2022 | |
| Currax Pharmaceuticals LLC | $14.77 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.